Ironwood Pharmaceuticals Chooses AstraZeneca as Chinese Partner for Linaclotide
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 12 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1834 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca has partnered with Ironwood Pharmaceuticals for the co-development and co-commercialisation in China of linaclotide, which is approved in the US for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS